Persistent EGFR/K-RAS/SIAH pathway activation drives chemo-resistance and early tumor relapse in triple-negative breast cancer.
Cancer Drug Resist
; 5(3): 691-702, 2022.
Article
em En
| MEDLINE
| ID: mdl-36176751
EGFR/K-RAS/SIAH pathway activation in TNBC; Triple-negative breast cancer (TNBC); and treatment optimization; chemo-resistance; detection of chemo-resistance; neoadjuvant chemotherapy prognosis; patient risk stratification; precision quantification of therapy efficacy; seven in absentia (SINA) and human homologs of SINA (SIAH) E3 ligase; ubiquitin-mediated proteolysis
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article